Canaccord Genuity Reiterates a ‘Buy’ Rating on Exactech (EXAC); Silverbolt Acquisition Adds Fifferentiated MIS Product

Canaccord Genuity reiterates a ‘Buy’ rating on Exactech, Inc. (NasdaqEXAC), lowers PT from $26 to $23.50.

Canaccord analyst says, “We reiterate our rating as the acquisition further strengthens the company’s spine portfolio with the addition of a minimally invasive system. Furthermore, given the dynamics of the spine market right now, the new products provide Exactech’s reps additional breadth to bid on the RFPs (request for proposals) that hospitals are putting out, giving the company opportunities to take market share.”

To see all the upgrades/downgrades on shares of EXAC, visit our Analyst Ratings page.

Shares are down $0.31 (-2.05%) today to $14.83 and are getting closer to the 52-wk low ($13.54 – 22.34).


Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Themed By teapots